Staquicini, D I
D'Angelo, S
Ferrara, F
Karjalainen, K
Sharma, G
Smith, T L
Tarleton, C A
Jaalouk, D E
Kuniyasu, A
Baze, W B
Chaffee, B K
Hanley, P W
Barnhart, K F
Koivunen, E
MarchiĆ², S
Sidman, R L
Cortes, J E
Kantarjian, H M
Arap, W
Pasqualini, R
Article History
Received: 9 May 2017
Revised: 19 June 2017
Accepted: 30 June 2017
First Online: 5 December 2017
Competing interests
: RP and WA are founders and equity stockholders of Alvos Therapeutics (Arrowhead Pharmaceuticals Research Corporation, Pasadena, CA, USA). Arrowhead Pharmaceuticals has licensed rights to patents and technologies described in this article. RP and WA are inventors on patent applications and intellectual property related to this work and will be entitled to standard royalties if licensing and/or commercialization occur. The University of New Mexico Health Sciences Center manages and monitors these arrangements, along with the University of Texas MD Anderson Cancer Center. The other authors declare that they have no competing interests.